Scholarlink

Purpose <p>Bacillus Calmette-Guérin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response.</p> Methods <p>Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80&#xa0;mg, ≥ 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort). </p> Results <p>The median follow-up period was 45&#xa0;months (interquartile range (IQR): 14–83&#xa0;months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32–0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates.</p> Conclusion <p>This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationship between urinary pH and efficacy of Bacillus Calmette-Guérin treatment in patients with carcinoma in situ of the bladder

  • 期刊论文

  • 发表日期：

    2025年5月19日

查看全文
  • Ryo Yamashita,
  • Takashi Sugino,
  • Akifumi Notsu,
  • Yuichiro Nakaya,
  • Kana Ito,
  • Yuma Sakura,
  • Hideo Shinsaka,
  • Masato Matsuzaki,
  • Masashi Niwakawa,
  • Eiji Kikuchi

摘要

Purpose

Bacillus Calmette-Guérin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response.

Methods

Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort).

Results

The median follow-up period was 45 months (interquartile range (IQR): 14–83 months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32–0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates.

Conclusion

This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment.